MUC1号
免疫系统
糖肽
抗原
癌症疫苗
粘蛋白
癌症
免疫学
免疫疗法
糖蛋白
癌症免疫疗法
生物
医学
癌症研究
微生物学
生物化学
抗生素
遗传学
作者
Lixin Yin,Yang Zhou,Sheng Hong,Feiqing Ding,Hui Cai
标识
DOI:10.1002/cbic.202200805
摘要
Cancer vaccines are based on a vaccinology strategy whereby the patient's immune system is harnessed to induce a specific immune response to kill cancer cells and comprises two categories: prophylactic and therapeutic. Glycoprotein mucin 1 (MUC1), which is overexpressed and poorly glycosylated on cancer cells, is one of the most promising candidates for the development of new cancer vaccines. However, it should be noted that mucin-like glycopeptides are poorly immunogenic and unable to elicit effective and long-lasting immune responses. Therefore, MUC1-derived tumor antigens need to be conjugated with immune activators. This review focuses on the synthesis of MUC1 glycopeptides, provides an overview of recently advanced designs of vaccines based on MUC1, and compares the advantages and disadvantages of the various strategies devised to date.
科研通智能强力驱动
Strongly Powered by AbleSci AI